KarXT Cuts PANSS Scores in Acute Schizophrenia Without Dopamine Blockade
This phase 3 trial of a first-in-class muscarinic agonist plus peripheral anticholinergic gives pharmacists an early look at efficacy and a GI and cardiovascular adverse event profile distinct from D2 antagonists.
KarXT shows promise in reducing schizophrenia symptoms significantly.
KarXT is being evaluated as a new treatment for schizophrenia, potentially offering an alternative to current therapies. KarXT significantly lowered the Positive and Negative Syndrome Scale (PANSS) total score by 9.6 points compared to placebo (p<0.0001). As a CNS-focused study, it lacks direct applicability to gastroenterology or hepatology. It is potentially impactful for neuropharmacology. KarXT shows promise as a novel schizophrenia treatment with significant and clinically meaningful efficacy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Correll CU, Miller AC, Sawchak S, Kaul I, Paul SM, Brannan SK
Citation:Correll CU, Miller AC, Sawchak S, et al. Safety and efficacy of KarXT (Xanomeline Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial. CNS spectrums. 2023;28(2):220. doi:10.1017/S1092852923001360